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Therapeutic effects of oral nutritional supplementation during The mortality and morbidity rate is unacceptably high
hemodialysis. in end-stage renal disease (ESRD) patients, especially
Background. Protein-calorie malnutrition is common in in patients on chronic hemodialysis (CHD) therapy [1].
chronic hemodialysis (CHD) patients and correlates with mor- An important predictor of poor outcome in this patient
bidity and mortality in these patients. There are limited trials
population is the extent of protein-calorie malnutritionevaluating the efficacy of oral nutritional supplementation in
(PCM) [2–4]. PCM is not only associated with poor out-malnourished CHD patients.
comes, but it is also highly prevalent and can be foundMethods. Eighty-five CHD patients with evidence of malnu-
trition were included in this prospective study. Patients were in approximately 40% of CHD patients [5].
followed for a 3-month baseline period during which they re- Given the significance of this problem, multiple strate-
ceived conventional nutrition counseling. This was followed by gies have been developed to improve nutritional status
an intervention period, during which an oral nutritional supple- of CHD patients. While active nutritional intervention
ment specifically formulated for CHD patients was given over to maintain an adequate protein and calorie intake isa period of 6 months. An important element of this study was
encouraged in malnourished CHD patients, such nutri-that the nutritional supplement was provided during dialysis
tional counseling is usually unsuccessful in optimizing theto ensure compliance. Serial measurements of nutritional pa-
dietary intake [6, 7]. Provision of supplemental enteralrameters including concentrations of serum albumin, prealbu-
min, transferrin as well as body mass index (BMI) and subjective and/or parenteral nutritional products in order to replen-
global assessment (SGA) were obtained during the 9-month ish body protein and energy stores has been proposed
period. to improve the nutritional status of these patients [6, 8, 9].
Results. The nutritional parameters did not change during Very few large-scale prospective studies of intradialytic
the 3-month baseline period. Following administration of oral parenteral nutrition (IDPN) have been carried out and
supplementation during hemodialysis, there were significant
these have produced mixed results [10]. Further, this typeincreases in concentrations of serum albumin (from 3.33 
of therapy is costly and is currently severely restricted by0.32 g/dL at baseline, to 3.65  0.26 g/dL at month 6, P 
Medicare regulations. Similarly, there are only a limited0.0001) and serum prealbumin (from 26.1 8.6 mg/dL at base-
number of studies evaluating the efficacy of oral nutri-line, to 30.7  7.4 mg/dL at month 6, P  0.002). Mean SGA
score increased 14% by the end of the study (P  0.023). tional supplementation in CHD patients and these also
Although BMI and estimated dry weight increased also, these have shown conflicting results [11–13]. Importantly, in
changes were not statistically significant. Serum transferrin did most of these studies, the oral nutritional supplementa-
not change during the study period. tion was given to the patient to take at home, which
Conclusion. Oral nutritional supplementation given during
limited the ability of investigators to monitor compli-hemodialysis improves nutritional markers in malnourished
ance.CHD patients.
This prospective study evaluated the nutritional im-
pact of oral nutritional supplementation given during
the hemodialysis (HD) procedure in a large group ofKey words: serum albumin, serum prealbumin, subjective global assess-
malnourished CHD patients. Our results showed thatment, chronic hemodialysis, diet and ESRD, protein calorie malnutri-
tion. oral nutritional supplementation given over a period of
6 months is effective in improving several nutritionalReceived for publication December 31, 2001
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Table 1. Demographic characteristics of the study patients (N  85) serum transferrin, and body mass index (BMI). In addi-
tion, SGA was performed every 3 months. Sample collec-Gender male/female 35 M (41.2%), 50 F (58.8%)
Age years 62.315.4 tion was obtained within each month of data analysis in
Race 40.1% Caucasian a nonfasting state prior to the hemodialysis session.48.6% African American
At each center a renal dietitian collected the data11.2% Hispanic
Diabetes mellitus 46.3% and monitored the patients’ nutritional intake during the
study. The dietitian at each clinic performed 48-hour
diet history and SGA during the 3-month observation
period and at three-month intervals. The SGA was
METHODS scored according to McCann’s reference where 6 to 7
indicates no risk of malnutrition, 3 to 5 indicates mild-Patient characteristics
to-moderate risk of malnutrition, and 1 to 2 indicatesA total of 85 patients on CHD were recruited for the
severe risk of malnutrition [14]. Total supplemented pro-study purposes. The inclusion criteria included: CHD
tein and calories also were documented during the study.therapy for at least 6 months, age 18 years or older, no
During the intervention period, an oral nutritionalhospitalization within the last 3 months prior to the study
supplement specifically formulated for CHD patientsintervention, and mean serum albumin of 3.7 g/dL or
was prescribed by their physician (Nepro; Ross Prod-mean serum prealbumin of 30 mg/dL. Patients with
ucts Division, Abbott Laboratories, Abbott Park, IL,liver disease, active malignancy (other than skin) or those
USA). Patients were given one can of Nepro duringwho recently had undergone major surgery (up to 6
each hemodialysis session. One can of Nepro is 8 ouncesmonths) were not included in the study. The study proto-
(237 mL) and contains 16.6 grams of protein, 22.7 gramscol was approved by Western Institutional Review Board
of fat and 52.8 grams of carbohydrate. Each can ofand consent was obtained from all study patients. The
Nepro provides 475 calories. Patients unable to ingestdemographic characteristics of the study population at
more than 75% of the prescribed supplement over abaseline are depicted in Table 1. The mean age of the
month were dropped from the study.
patients was 62.3 years ( 15.4; range 24 to 92 years),
All patients were dialyzed with biocompatible mem-
approximately 60% were female and 50% were African branes. Patients’ routine laboratory parameters were
American. kept within acceptable ranges through established proto-
cols. Recombinant human erythropoietin and intrave-Study design
nous iron were prescribed to keep hematocrit within the
The study was prospective design with patients serving range of 33 to 36%. Urea reduction ratio (URR) and
as their own controls. Patients were recruited from a Daugirdas formula for Kt/V were used once a month
total of 10 hemodialysis centers from a pool of 757 CHD during the study period to assess the dose of dialysis,
patients. Patients who were eligible by inclusion criteria with a goal of URR70% and Kt/V 1.4. During study
first entered into a 3-month baseline period, followed by period, all morbid events for all study patients were
a 6-month intervention period. Routine dietary counsel- recorded.
ing and intervention were provided during the baseline All measurements were done at a specialized ESRD
period. All study patients had been given individualized clinical and special chemistry laboratory (Renalab, Jack-
dietary goals to achieve adequate protein and calories, son, MS, USA). Serum albumin was analyzed using the
monitoring monthly laboratory indices for intervention bromcresol green technique. Serum prealbumin was ana-
as needed. Patients received nutrition intervention by a lyzed by an antigen-antibody complex assay, and serum
renal dietitian with individualized nutritional assess- transferrin was analyzed by turbidimetric reading.
ments involving diet histories, laboratory trending and
Statistical analysisquarterly SGA to evaluate visceral and somatic protein
stores. Patients who were found to have weight loss The primary outcome of this study was time-depen-
trends of 5% in the prior one to three months or a dent changes in nutritional parameters during the inter-
significant change in serum albumin, serum prealbumin vention period. The trends of the nutritional markers
or serum transferrin were targeted for focused nutri- over the time were estimated using the restricted/resid-
tional support. Nutritional support consisted of encour- ual maximum likelihood (REML)-based mixed effect
aging patients to enhance their food intake with the model to adjust the intra-correlation effect for the pa-
addition of small, frequent meals. This “routine” inter- tients who had multiple measurements. The model was
vention was continued during the study period. selected based on Akaike’s Information Criterion and
Throughout the study, serial measurements of nutri- Schwarz’s Bayesian Criterion. Correlations among the
tional variables were obtained on a monthly basis. These nutritional parameters at baseline were estimated using
the Pearson Correlation Coefficients method. Pairedparameters included serum albumin, serum prealbumin,
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Table 2. Study variables (meanSD) at follow-up time points during the study period (N  85)
Baseline 1 month 2 months 3 months 4 months 5 months 6 months
N  85 N  68 N  61 N  49 N  48 N  42 N  39
Serum albumina g/dL 3.330.32 3.620.35 3.640.33 3.720.29 3.680.30 3.640.32 3.650.26
Serum prealbumina mg/dL 26.18.57 27.18.14 27.88.31 28.68.60 28.48.10 28.98.07 30.77.36
Serum transferrin mg/dL 15639.5 15936.2 15936.4 16544.3 15832.5 15936.3 15637.4
SGAb 4.941.23 ND ND 5.390.89 ND ND 5.640.90
BMI 25.86.10 25.56.07 266.09 26.85.89 26.35.97 26.65.71 27.15.43
ND is not done.
a Denotes P  0.01 by mixed procedure
b Denotes P  0.05 by t test
Fig. 1. Increase in serum albumin concentrations during the interven-
tion period. “0” denotes baseline period and N is the number of patients.
Fig. 2. Increase in serum prealbumin concentrations during the inter-
vention period. “0” denotes baseline period and N is the number of
patients.
t test with Bonferroni correction was applied to examine
the difference between the baselines, 3-month and
notable numerical and/or statistically significant change6-month follow-up for each nutritional parameter.
in study variables. Therefore, the mean of the 3-monthAll tests of significance were two-sided, and differ-
data in the baseline period was used for “baseline” val-ences were considered statistically significant when the
ues. Following administration of oral supplementation,P-value 0.05. All data are expressed as means ( SD).
significant improvements in nutritional parameters wereSAS version 8.2 was used for all analyses.
noted. Table 2 depicts the mean ( SD) of the monthly
results for all the parameters studied for the whole study
RESULTS group. As can be seen, there were significant increases
A total of 85 patients (35 male, 50 female) were in- in serum albumin (from 3.33  0.32 g/dL at baseline to
cluded in the study. Among these patients, 27 patients 3.65  0.26 g/dL at month 6) and serum prealbumin
dropped out during the study period (10 male/17 female) concentrations (from 26.1  8.57 mg/dL at baseline to
due to non-compliance. Of these patients, 17 (20%, 6 30.7  7.36 mg/dL at month 6) during the study period.
male/11 female) refused to ingest the oral supplementa- These changes were statistically significant (P  0.0001
tion and 10 patients (11.7%, 4 male/6 female) were cen- and P  0.002 by mixed model analysis, respectively).
sored because of decreased compliance (ingesting75% Figures 1 and 2 graphically depict these changes. The
of prescribed nutritional supplementation). Addition- increase in serum albumin was 11% at the end of 3
ally, during the study period, 7 patients transferred out months and 9% at the end of six months. Serum prealbu-
and one patient was transplanted. Eleven patients min concentrations increased 9% by the third month and
(12.9%) died during the intervention period. Thirty-nine 17% at the end of six months.
patients were able to complete the entire study. The Another nutritional variable that improved during the
number of patients at each time point is depicted in intervention period was SGA (Fig. 3). Mean subjective
Table 2. global assessment score increased 14% by the end of the
intervention period compared to baseline (4.94 1.23 toDuring the 3-month baseline period, there was no
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the study variables in this subgroup during the study
period. When compared to the trends observed in 68
patients who remained in the study, these patients had
statistically significant lower concentrations of serum al-
bumin and prealbumin (P  0.05, for both).
DISCUSSION
While the importance of PCM is well established in
CHD patients, studies evaluating the effectiveness of
nutritional therapies are limited. In this prospective con-
trolled study, we were able to show that oral nutritional
supplementation, specifically given during hemodialysis
treatment over a period of 6 months, significantly im-
proves nutritional parameters in malnourished CHD pa-
Fig. 3. Increase in the subjective global assessment (SGA) score during tients.
intervention period. *P  0.05 versus baseline. Given the extent and importance of PCM, it is not
surprising that PCM is related to multiple factors. Among
these, decreased protein and energy intake is an impor-
tant one, because it is potentially treatable. Several re-5.64  0.90, P  0.023). Although there were numerical
ports indicated that protein and energy intake in CHDincreases in BMI (from 25.8  6.10 kg/cm2 to 27.1 
patients are less than their recommended value [15, 16].5.43 kg/cm2) and estimated dry weight (from 73.1  15.3
Decreased nutrient intake can be related to several fac-kg to 76.1  16.2 kg) during the study period, these
tors, including uremic milieu, gastroparesis, hormonalchanges did not reach statistical significance. Serum
and metabolic abnormalities and certain co-morbiditiestransferrin concentration did not demonstrate a statisti-
[17–21]. Nutritional counseling generally shows little suc-cally significant change during the study period.
cess in restoring nutrient intake to required levels inSince the study patients were followed prospectively
CHD patients. Nutritional supplementation has been afor 3 months prior to initiation of nutritional interven-
recommended intervention to overcome this problem;tion, we compared the slopes in study variables during
however, as mentioned earlier, the results of the studiesthe baseline control period versus trends during inter-
have been mixed, and for oral supplementation, whichvention periods (break point analysis/piece-wise regres-
is generally given to patients to take at home, compliancesion analysis). As expected, there were significant differ-
has been a constant challenge.ences in serum albumin and serum prealbumin slopes
The present study clearly indicates that oral supplemen-between these periods (P  0.05 for serum albumin and
tation given during hemodialysis may have nutritionalserum prealbumin). Baseline demographic characteristics
benefits in malnourished CHD patients. Surprisingly,(race, gender, age, diabetes mellitus) of the study patients
there are only limited numbers of studies evaluating thedid not predict the changes observed during the interven-
efficacy of oral nutritional supplementation in CHD pa-tion phase.
tients. Earlier studies with oral supplementation haveDietary protein intake estimated by dietary recall
shown various degrees of improvement, with many show-method did not show statistically significant changes dur-
ing no improvement in nutritional parameters [12, 13, 22,ing the study (0.82  1.02 g/kg/day at baseline, 0.89 
23]. More recently, Eustace et al reported the beneficial1.02 g/kg/day at month 3, 0.83  1.06 g/kg/day at month
effect of oral amino acid supplements using prospective,6). Therefore, it is likely that the changes observed dur-
randomized, placebo-controlled pilot study [24]. Our re-ing the intervention phase reflect the impact of nutri-
sults also are consistent with these reports and extendtional supplementation. Finally, there were no significant
these findings to a larger patient population. Impor-differences in hospitalization rates between the observa-
tantly, although the design of the study was not random-tion and the intervention periods.
ized, the “no-intervention” 3-month baseline period asDuring the study, 17 patients dropped out within 2
well as the subset of patients who met the inclusionmonths of initiation of the intervention period due to
criteria but were non-compliant with the oral supplemen-non-compliance, prior to ingesting a significant amount
tation provided another reference group and highlightedof nutritional supplementation. Since follow-up data
the beneficial effects of oral supplementation. These ben-were available for these 17 patients (up to 5 months
eficial changes appeared to have occurred in the absenceafter drop-out), we analyzed the trends in nutritional
of an increase in dietary intake outside the dialysis fa-parameters in this subgroup. There were no notable nu-
merical and/or statistically significant changes in any of cility.
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In addition to inadequate dietary nutrient intake, the is high and its use is severely restricted with Medicare-
hemodialysis procedure per se has been considered a imposed onerous requirements for patients to qualify.
catabolic process and implicated in the development of Due to the cost of the intravenous supplementation and
protein calorie malnutrition. Indeed, the hemodialysis complexities of selecting eligible patients according to
procedure is associated with certain catabolic conse- Medicare criteria, there are no prospective randomized
quences. Earlier studies by our laboratory have shown long-term studies designed to evaluate the efficacy of
the importance of adequate dose of dialysis and the use intensive parenteral nutritional supplementation in CHD
of appropriate hemodialysis membranes to improve the patients. In a retrospective study, Capelli et al observed
nutritional status in chronic hemodialysis patients [19, 25]. modest increase in survival in CHD patients who re-
While these aspects of hemodialysis are well-understood ceived IDPN for 9 months [31]. In another retrospective
and such preventive measures have been used in our study, Chertow et al analyzed a large group of CHD
current study, certain other characteristics of the hemo- patients who received IDPN and compared them with
dialysis procedure still predispose CHD patients to ca- those patients who did not receive IDPN [32]. They
tabolism, in particular the inevitable losses of nutrients reported reduction in the relative risk of death in the
in the dialysate, the lack of free access to food during group of patients with low albumin levels who were given
hemodialysis and the induction of catabolic cascades IDPN. Nevertheless, because of several inherent prob-
such as systemic inflammatory response syndrome. In- lems in the design of these studies, the data supporting
deed, studies by our laboratory and others have indicated the use of IDPN were considered weak [10]. Oral nutri-
that the procedure of hemodialysis treatment leads to tional supplementation, which has been shown to be
increased catabolism of whole-body and muscle protein effective in CHD patients in this study, has practical and
and a net loss of protein stores as well as increased financial advantages over IDPN. However, before oral
energy expenditure [26, 27]. Based on these studies, it supplementations can be recommended for general use,
is estimated that 6 to 8 grams of amino acids (approxi- their efficacy, especially compared to IDPN, must be
mately 40 grams of protein) are lost into the dialysate and proven with additional studies.
200 kcal of extra energy is utilized during hemodialysis While our results showed a significant benefit of oral
[28–30]. Importantly, the protein and energy losses are nutritional supplementation, one should consider poten-
accompanied by significant muscle catabolism to replen- tial limitations of the study. Most importantly, the design
ish plasma amino acid and protein pool. Equally impor- was not randomized or placebo controlled. However, in
tant, these studies indicate a lack of adequate compensa- order to minimize bias, we implemented a baseline con-
tory protein anabolism, resulting in a net increase in trol period followed by an intervention period with all
protein catabolism during hemodialysis. Further, most
aspects of therapy (dialysis prescription, nutritional coun-
patients are not allowed to consume food during this
seling, etc.) remaining constant during these two periods.highly catabolic 3 to 4 hour period. Based on this infor-
There was a significant difference between baseline andmation, we elected to administer the supplementation
intervention periods. Another important issue is theduring hemodialysis, at a time when the amino acid losses
safety of this mode of supplementation. During the inter-into the dialysate are maximized and the catabolism is
vention period, we did not observe any increase in theat its peak. Our results suggest that, the nutritional sup-
intradialytic side effects such as hypotension, vomiting,plementation provided during this time indeed compen-
muscle cramps, which is not unusual when patients takesates for the hemodialysis-associated catabolism.
large meals during hemodialysis. Although this might beAnother rationale for the application of supplementa-
the result of the small volume of supplement that wetion during hemodialysis is to assure compliance. When
introduced, it also demonstrates the safety of this modeprovided for intake at home, compliance with the supple-
of supplementation.mentation has been an issue that has hampered the evalu-
In conclusion, this pilot multicenter prospective studyation of the benefits of oral supplementation. The overall
demonstrates that oral nutritional supplementation givencompliance rate was 69% during the study. Of note, only
during hemodialysis is an effective therapy for malnour-20% of the patients dropped out due to taste dislike or
ished CHD patients. Although a fraction of patientsgastrointestinal intolerance associated with the nutri-
withdrew from the study for non-compliance, adminis-tional supplementation. This ratio is consistent with
tration of supplement during hemodialysis seems to belarge-scale studies in terms of patient compliance. There-
a promising strategy to overcome this problem. Never-fore, our study suggests that nutritional supplementation
theless, our study should be considered as a pilot projectduring hemodialysis may improve nutritional status par-
and the findings presented should be validated by larger,ticularly in patients who have good compliance.
randomized clinical trials. In the meantime, as a practicalAnother important aspect of oral nutritional supple-
measure, oral nutritional supplementation should be at-mentation is its financial advantages over intradialytic
parenteral nutrition (IDPN). Currently, the cost of IDPN tempted in malnourished CHD patients if other factors
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